文献速递生殖医学

促卵泡激素δ在重复卵巢刺激中用于体外受精:一项对照、评估者盲法3期安全性试验

Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial.
PubMed 文献 · Reprod Biomed Online · 2018-12-14

本研究在既往随机试验中接受促卵泡激素δ或促卵泡激素α初始刺激的体外受精/卵胞浆内单精子注射患者中,评估重复周期(第2、3周期)促卵泡激素δ的免疫原性。第2、3周期分别有513例和188例女性按第1周期随机分组治疗,剂量基于前一周期卵巢反应。促卵泡激素δ治疗诱导的抗FSH抗体发生率在第2、3周期分别为0.8%和1.1%,与第1周期(1.1%)相似,无中和抗体。结论认为促卵泡激素δ在重复卵巢刺激中免疫原性潜力低,并证实其重复周期给药方案的适当性。

要点

  • 促卵泡激素δ治疗诱导的抗FSH抗体发生率第2周期0.8%、第3周期1.1%,与第1周期1.1%相似。
  • 未检测到中和性抗FSH抗体,预存抗FSH抗体女性可安全接受促卵泡激素δ治疗。
  • 促卵泡激素δ与促卵泡激素α在获卵数、持续妊娠率和活产率方面结果相似。

核心结论

  • 试验表明促卵泡激素δ在重复卵巢刺激中免疫原性潜力低,并证实其重复周期给药方案的适当性,疗效和安全性有记录。

研究设计与样本

  • 对照、评估者盲法试验,纳入体外受精/卵胞浆内单精子注射患者,在既往随机试验第1周期接受促卵泡激素δ或促卵泡激素α初始刺激后,进入重复周期(第2、3周期)卵巢刺激。
  • 第2、3周期分别有513例和188例女性按第1周期随机分组治疗,剂量基于前一周期卵巢反应。

主要发现

  • 促卵泡激素δ治疗诱导的抗FSH抗体发生率在第2周期为0.8%,第3周期为1.1%,与第1周期(1.1%)相似。
  • 未检测到中和性抗FSH抗体,预存抗FSH抗体女性接受促卵泡激素δ治疗未增强免疫反应。
  • 促卵泡激素δ与促卵泡激素α的平均获卵数:第2周期9.2 vs 8.6,第3周期8.3 vs 8.9。
  • 促卵泡激素δ与促卵泡激素α的持续妊娠率:第2周期27.8% vs 25.7%,第3周期27.4% vs 28.0%;活产率:第2周期27.4% vs 25.3%,第3周期26.3% vs 26.9%。
  • 抗FSH抗体的存在不影响卵巢反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: To evaluate the immunogenicity of follitropin delta in repeated ovarian stimulation. DESIGN: Controlled, assessor-blind trial in IVF/intracytoplasmic sperm injection patients undergoing repeated cycles of ovarian stimulation (cycles 2 and 3), following initial stimulation with follitropin delta or follitropin alfa (cycle 1) in a preceding randomized trial. In cycles 2 and 3, 513 and 188 women, respectively, were treated as randomized in cycle 1, with dosing based on ovarian response in the previous cycle. RESULTS: The incidence of treatment-induced anti-FSH antibodies with follitropin delta was 0.8% and 1.1% in cycles 2 and 3, respectively, which was similar to the incidence in cycle 1 (1.1%). No antibodies were of neutralizing capacity. Women with pre-existing anti-FSH antibodies were safely treated with follitropin delta without boosting an immune response. Treatment with follitropin delta and follitropin alfa gave similar outcomes for mean number of oocytes retrieved (9.2 versus 8.6 [cycle 2]; 8.3 versus 8.9 [cycle 3]), ongoing pregnancy (27.8% versus 25.7%; 27.4% versus 28.0%) and live birth rates (27.4% versus 25.3%; 26.3% versus 26.9%). The presence of anti-FSH antibodies did not affect the ovarian response. CONCLUSIONS: The trial demonstrated the low immunogenicity potential of follitropin delta in repeated ovarian stimulation, and confirmed the appropriateness of the follitropin delta dosing regimen in repeated cycles, with documented efficacy and safety.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Bosch E, Havelock J, Martin FS, et al. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reprod Biomed Online. 2018. PMID: 30594482. doi:10.1016/j.rbmo.2018.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。